News about Global Pharma

Arrowhead Pharmaceuticals Reports Long-Term Efficacy, Safety Data for Plozasiran

Arrowhead Pharmaceuticals reports long-term phase 2b data showing plozasiran reduces triglycerides by 83 percent in sHTG patients, with no pancreatitis events and sustained improvements in lipid markers and safety.

Global Pharma | 30/03/2026 | By News Bureau |  153

Artelo Biosciences Expands ART27.13 as Companion Therapy to GLP-1 Treatments

Artelo Biosciences advances ART27.13 as a potential companion therapy to GLP-1 treatments, aiming to preserve muscle mass during weight loss, supported by new preclinical studies, patent filings and published research.

Global Pharma | 26/03/2026 | By News Bureau |  100

Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial

Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.

Global Pharma | 25/03/2026 | By News Bureau |  115

Novartis Presents New Data on Skin Disease Treatment at AAD 2026

Novartis presents new AAD 2026 data showing early symptom relief and long-term control in skin diseases, with Rhapsido REMIX analysis in CSU and Cosentyx data in hidradenitis suppurativa and psoriasis.

Global Pharma | 25/03/2026 | By News Bureau |  187

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.

Global Pharma | 24/03/2026 | By News Bureau |  107

Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer

Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).

Global Pharma | 21/03/2026 | By News Bureau

IntraBio Submits sNDA for Levacetylleucine in Ataxia-Telangiectasia

IntraBio has submitted an sNDA to the US Food and Drug Administration (FDA) for Levacetylleucine, marking the first regulatory filing seeking approval for the treatment of Ataxia-Telangiectasia.

Global Pharma | 21/03/2026 | By News Bureau

Illumina, Labcorp Expand Partnership to Advance Precision Oncology

Illumina and Labcorp have expanded their collaboration to strengthen precision oncology through wider use of next-generation sequencing (NGS) technologies.

Global Pharma | 20/03/2026 | By Darshana |  152

Mabtech, Sai Life Sciences Partner to Expand Advanced Immunology Services in the U.S.

Mabtech and Sai Life Sciences collaborate to deploy EYRA multiplex platform in Boston, enhancing access to advanced immune profiling for biopharma and biotech research.

Global Pharma | 19/03/2026 | By News Bureau |  134

FTC Tracks Pharma Strategies as Patent Cliff Approaches

The US Federal Trade Commission (FTC) is keeping a close watch on how pharmaceutical companies respond as several blockbuster drugs approach the end of their patent life. The regulator is particularly concerned about practices that could delay the entry of lower-cost generic medicines.

Global Pharma | 18/03/2026 | By Darshana |  135